Apatinib as targeted therapy for sarcoma
PDF | HTML | How to cite
Metrics: PDF 2076 views | HTML 2445 views | ?
Feng Li1,2,3,4, Zhichao Liao1,2,3,4, Chao Zhang1,2,3,4, Jun Zhao1,2,3,4, Ruwei Xing1,2,3,4, Sheng Teng1,2,3,4, Jin Zhang1,2,3,4, Yun Yang1,2,3,4 and Jilong Yang1,2,3,4
1Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, People’s Republic of China
2National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, People’s Republic of China
3Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, People’s Republic of China
4Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, People’s Republic of China
Jilong Yang, email: [email protected]
Keywords: apatinib; sarcoma; targeted therapy; efficacy; safety
Received: December 13, 2017 Accepted: February 25, 2018 Published: May 11, 2018
Sarcomas are a group of malignant tumors originating from mesenchymal tissue with a variety of cell subtypes. Despite several major treatment breakthroughs, standard treatment using surgery, radiation, and chemotherapy has failed to improve overall survival. Therefore, there is an urgent need to explore new strategies and innovative therapies to further improve the survival rates of patients with sarcomas. Pathological angiogenesis has an important role in the growth and metastasis of tumors. Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFRs) play a central role in tumor angiogenesis and represent potential targets for anticancer therapy. As a novel targeted therapy, especially with regard to angiogenesis, apatinib is a new type of small molecule tyrosine kinase inhibitor that selectively targets VEGFR-2 and has shown encouraging anticancer activity in a wide range of malignancies, including gastric cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, and sarcomas. In this review, we summarize the preclinical and clinical data for apatinib, focusing primarily on its use in the treatment of sarcomas.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.